ClinicalTrials.gg
CompletedNCT01794780Updated Sep 26, 2019Results posted

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

A Phase 4 interventional study of LABA based treatment: indacaterol and LAMA based treatment: tiotropium in COPD, sponsored by Novartis Pharmaceuticals. Completed at 2 sites in China. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,229
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. indacaterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
3rd of 57
2,229 · median 154
Started
2013
with 5 others
Phase 4
20 of 57
none open now
Registered
45th of 57
by date
Lead sponsor
28 of 57
Novartis Pharmaceuticals

Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 6 that started in 2013, is one of 20 in phase 4, and was the 45th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About indacaterol

indacaterol: first FDA approval 2011 (ARCAPTA NEOHALER), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.

The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set.

A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.

03

Conditions studied

  • COPD

Keywords

  • COPD
  • Chronic obstructive pulmonary disease (COPD),
  • Chronic obstructive lung disease (COLD),
  • Chronic obstructive airway disease (COAD),
  • Cronchitis,
  • Emphysema
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide
  • Physician-diagnosis of
  • COPD patients requiring long-acting bronchodilator treatment
  • Patients with spirometry available at baseline

Exclusion criteria

Exclusion Criteria:

  • Patients who have a diagnosis of asthma.
  • Patients who had been hospitalized for a exacerbation in the 4 weeks prior to Visit 1.
  • Current clinical diagnosis of other chronic respiratory illnesses
  • Concurrent participation in a clinical trial or use of an drug.
  • Active or history of malignancy of any organ system
  • Pregnant or nursing (lactating) women
  • Women of with no Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,229 participants (actual)

Study arms

  • Experimental
    Indacaterol

    LABA: Indacaterol, once a day, 150μg each time

    Drug: LABA based treatment: indacaterol

  • Experimental
    Tiotropium Bromide

    LAMA: Tiotropium Bromide, once a day, 18 μg

    Drug: LAMA based treatment: tiotropium

  • Experimental
    Salmeterol/Fluticasone

    LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg

    Drug: LABA/ICS based treatment: salmeterol/fluticasone

  • Experimental
    Budesonide/ formoterol

    Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg

    Drug: LABA/ICS based treatment: budesonide/formoterol

  • Experimental
    Indacaterol +Tiotropium

    Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg

    Drug: LABA based treatment: indacaterol · Drug: LAMA based treatment: tiotropium

  • Experimental
    LABA/ICS (Or budesonide/ formoterol)+ Tiotropium

    Salmeterol / fluticasone Or budesonide / formoterol

    Drug: LAMA based treatment: tiotropium · Drug: LABA/ICS based treatment: salmeterol/fluticasone · Drug: LABA/ICS based treatment: budesonide/formoterol

  • Experimental
    Oral theophylline

    Drug: theophylline based treatment

  • Experimental
    Other treatment

    non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"

    Drug: Other treatment

Interventions

  • LABA based treatment: indacaterol

  • LAMA based treatment: tiotropium

  • DrugLABA/ICS based treatment: salmeterol/fluticasone

    Drug pages: Salmeterol Xinafoate · Fluticasone

    LABA/ICS based treatment: salmeterol/fluticasone

  • DrugLABA/ICS based treatment: budesonide/formoterol

    Drug pages: Budesonide · Formoterol

    LABA/ICS based treatment: budesonide/formoterol

  • Drugtheophylline based treatment

    theophylline based treatment

  • DrugOther treatment

    non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

    Time frame: Baseline,3 months

Secondary outcomes

  1. Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

    Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

    Time frame: Baseline,12 months

  2. COPD Exacerbation

    Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.

    Time frame: Baseline,12 months

  3. Change in Health Status Questionnaire MMRC

    The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.

    Time frame: Baseline,3,6,9,12 months

  4. Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score

    The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.

    Time frame: Baseline,3,6,9,12 months

  5. Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.

    Time frame: Baseline,3,6,9,12 months

07

Results

Posted Sep 26, 2019

Participant flow

A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.

Participant flow — Overall Study
MilestoneIndacaterolTiotropium BromideSalmeterol/FluticasoneBudesonide/ FormoterolIndacaterol +TiotropiumLABA/ICS (Or Budesonide/ Formoterol)+ TiotropiumOral TheophyllineOther Treatment
Started32276813283963215430
Completed15180571200645211221
Not completed1796242833180429
Withdrew: Adverse event01200000
Withdrew: Death021410940
Withdrew: Lost to follow-up106416553299305
Withdrew: Withdrew informed consent71736904843
Withdrew: Other012252012441

Outcome measures

PrimaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the Long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

Time frame:
Baseline,3 months
Reported as:
Mean · Liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
LitersIndacaterolTiotropiumLABA/ICSIndacaterol + TiotropiumLABA/ICS + TiotropiumOral Theophylline
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)-0.042 ± 0.17420.006 ± 0.25370.033 ± 0.37900.022 ± 0.11570.011 ± 0.24170.012 ± 0.3405
SecondaryChange From Baseline in Forced Expiratory Volume in 1 Second (FEV1)

Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function. Pulmonary function tests were performed at study visits including FEV1, and Force Vital Capacity (FVC). These were performed 30 minutes before treatment and not more than 2 hours in advance after stopping the long-acting bronchodilators eight hours before visits. In order to reduce the variation between each test, the same instrument was used in the whole research process if condition allowed.

Time frame:
Baseline,12 months
Reported as:
Mean · Liters
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
LitersIndacaterolTiotropium BromideLABA/ICSIndacaterol +TiotropiumLABA/ICS + TiotropiumOral Theophylline
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)0.056 ± 0.2137-0.036 ± 0.23950.056 ± 0.43350.030 ± 0.0854-0.028 ± 0.22580.046 ± 0.3654
SecondaryCOPD Exacerbation

Number of COPD exacerbations evaluated over 12 months. COPD exacerbation is defined as a new onset or worsening of at least 1 respiratory major symptoms (e.g. dyspnea, cough, sputum volume or sputum purulence) for at least 3 consecutive days, which results in recorded treatment change (antibiotics/steroids/oxygen therapy) OR recorded COPD related hospitalization/Emergency visit. COPD exacerbation is not considered as adverse event, and should only be recorded in COPD e-CRF.

Time frame:
Baseline,12 months
Reported as:
Mean · COPD Exacerbations/year
COPD Exacerbation
COPD Exacerbations/yearIndacaterolTiotropium BromideSalmeterol/FluticasoneBudesonide/ FormoterolLABA/ICSIndacaterol +TiotropiumLABA/ICS + TiotropiumOral Theophylline
COPD Exacerbation1.1 ± 3.530.5 ± 1.891.1 ± 7.740.4 ± 1.890.9 ± 6.724.1 ± 5.460.8 ± 3.471.0 ± 3.57
SecondaryChange in Health Status Questionnaire MMRC

The mMRC scale is scored from 0 (less severe) to 4 (severe). 0 Not troubled with breathlessness except with strenuous exercise; 1 Troubled by shortness of breath when hurrying on the level or walking up a slight hill; 2 Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on the level; 3 Stops for breath after walking about 100 yards or after a few minutes on the level; 4 Too breathless to leave the house or breathless when dressing or undressing. The modified Medical Research Council (mMRC) Dyspnea Scale , is a five-item instrument (part of the Borg scale) to assess a patient's degree of breathlessness in relation to physical activity. Participants will be required to read a brief description of an activity and then select a statement that best describes their experience with dyspnea at Visit 101. The mMRC was assessed by the investigators at the scheduled visits.

Time frame:
Baseline,3,6,9,12 months
Reported as:
Number · Number of participants
Change in Health Status Questionnaire MMRC
Number of participantsIndacaterolTiotropium BromideLABA/ICSIndacaterol +TiotropiumLABA/ICS + TiotropiumOral Theophylline
Baseline scale item 044016116331
Baseline scale item 111114435422666
Baseline scale item 21483327121134
Baseline scale item 3336154311019
Baseline scale item 403190224
3 month Scale item 032410105420
3 month Scale item 1969364415752
3 month Scale item 2754203313326
3 month Scale item 31186705811
3 month Scale item 4026091
6 month Scale item 02239603715
6 month Scale item 1557290114943
6 month Scale item 2845138410520
6 month Scale item 3113541444
6 month Scale item 40350110
9 month Scale item 032411604520
9 month Scale item 1552256112740
9 month Scale item 243013129919
9 month Scale item 3114420415
9 month Scale item 4014091
12 month Scale item 012415004720
12 month Scale item 1561275213852
12 month Scale item 2233127110212
12 month Scale item 3210410324
12 month Scale item 4039091
SecondaryChange From Baseline in Questionnaire COPD Assessment Test (CAT) Score

The COPD assessment test (CAT) is a short instrument scale used to quantify the symptom burden of COPD and will be used to assess the health status of patients in this study. It consists of eight items, each presented as a semantic 6-point differential scale, providing a total score out of 40. A higher score indicates a worse health status. Scores of 0 - 10, 11 - 20, 21 - 30 and 31 - 40 represent a mild, moderate, severe or very severe clinical impact of COPD upon the patient.

Time frame:
Baseline,3,6,9,12 months
Reported as:
Mean · Score on a scale
Change From Baseline in Questionnaire COPD Assessment Test (CAT) Score
Score on a scaleIndacaterolTiotropium BromideLABA/ICSIndacaterol +TiotropiumLABA/ICS + TiotropiumOral Theophylline
3 Month-1.9 ± 5.12-2.1 ± 5.58-2.3 ± 5.68-1.9 ± 2.67-1.8 ± 5.96-1.8 ± 4.07
6 Month-1.9 ± 5.80-2.7 ± 5.78-2.7 ± 5.89-2.7 ± 5.01-2.2 ± 6.46-2.5 ± 5.65
9 Month-4.4 ± 5.27-3.1 ± 6.02-3.5 ± 6.66-9.0 ± 2.65-3.1 ± 6.49-3.1 ± 6.27
12 Month-5.1 ± 3.98-2.6 ± 6.74-4.1 ± 7.09-7.7 ± 0.58-3.7 ± 6.45-2.4 ± 7.25
SecondaryChange From Baseline Questionnaire Transition Dyspnea Index (TDI) Score

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. BDI/TDI was used to assess dyspnea from several aspects, caused by daily activities. These were evaluated by the investigators in the study at the scheduled study visits. The indices were to be evaluated by the same investigator.as far as possible.

Time frame:
Baseline,3,6,9,12 months
Reported as:
Mean · Units on a scale
Change From Baseline Questionnaire Transition Dyspnea Index (TDI) Score
Units on a scaleIndacaterolTiotropium BromideLABA/ICSIndacaterol +TiotropiumLABA/ICS + TiotropiumOral Theophylline
Baseline6.7 ± 2.276.6 ± 2.666.7 ± 2.665.4 ± 2.246.2 ± 2.607.1 ± 2.81
3 Month1.4 ± 2.611.2 ± 2.431.3 ± 2.590.4 ± 2.071.1 ± 2.500.9 ± 2.57
6 Month0.0 ± 2.451.0 ± 2.671.4 ± 2.59-0.5 ± 2.260.9 ± 2.361.2 ± 2.03
9 Month0.7 ± 1.230.9 ± 2.481.6 ± 2.781.0 ± 1.730.9 ± 2.321.4 ± 2.68
12 Month0.3 ± 1.701.0 ± 2.911.7 ± 3.091.0 ± 1.731.0 ± 2.571.6 ± 2.44

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Indacaterol—1/32 (3.1%)2/32 (6.3%)
Tiotropium—9/276 (3.3%)1/276 (0.4%)
Salemeterol/Fluticasone—22/813 (2.7%)14/813 (1.7%)
Budesonide/Formoterol—2/283 (0.7%)1/283 (0.4%)
Indacaterol + Tiotropium—2/9 (22.2%)1/9 (11.1%)
Salemeterol/Fluticasone(or Budesonide/Formoterol)+Tiotropium—11/632 (1.7%)5/632 (0.8%)
Oral Theophylline—6/154 (3.9%)1/154 (0.6%)
Other—1/30 (3.3%)1/30 (3.3%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventIndacaterolTiotropiumSalemeterol/FluticasoneBudesonide/FormoterolIndacaterol + TiotropiumSalemeterol/Fluticasone(or Budesonide/Formoterol)+TiotropiumOral TheophyllineOther
Cardiac disorderCardiac disorders0/320/2760/8130/2831/90/6320/1540/30
Infectious pneumoniaInfections and infestations0/322/2760/8130/2831/90/6320/1540/30
HypertensionVascular disorders0/320/2760/8130/2831/90/6320/1540/30
GoitreEndocrine disorders0/320/2760/8130/2830/90/6320/1541/30
Inguinal herniaGastrointestinal disorders1/320/2760/8130/2830/90/6320/1540/30
Respiratory failureRespiratory, thoracic and mediastinal disorders0/320/2762/8130/2830/90/6322/1540/30
Acute left ventricular failureCardiac disorders0/320/2760/8130/2830/90/6321/1540/30
Coronary artery diseaseCardiac disorders0/320/2760/8130/2830/90/6321/1540/30
Unstable anginaCardiac disorders0/320/2761/8130/2830/91/6321/1540/30
GastritisGastrointestinal disorders0/320/2760/8130/2830/90/6321/1540/30
Most frequent other events
Most frequent other events
EventIndacaterolTiotropiumSalemeterol/FluticasoneBudesonide/FormoterolIndacaterol + TiotropiumSalemeterol/Fluticasone(or Budesonide/Formoterol)+TiotropiumOral TheophyllineOther
PruritusSkin and subcutaneous tissue disorders0/320/2760/8130/2831/91/6320/1540/30
Upper respiratory tract infectionInfections and infestations2/321/27614/8131/2830/94/6321/1541/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)IndacaterolTiotropium BromideSalmeterol/FluticasoneBudesonide/ FormoterolIndacaterol +TiotropiumLABA/ICS (Or Budesonide/ Formoterol)+ TiotropiumOral TheophyllineOther TreatmentTotal
Mean66.12 ± 9.23868.93 ± 9.14567.00 ± 9.35367.02 ± 9.85869.49 ± 8.87367.74 ± 9.42767.86 ± 9.65266.14 ± 10.20567.50 ± 9.453
Sex: Female, Male
Sex: Female, Male(Participants)IndacaterolTiotropium BromideSalmeterol/FluticasoneBudesonide/ FormoterolIndacaterol +TiotropiumLABA/ICS (Or Budesonide/ Formoterol)+ TiotropiumOral TheophyllineOther TreatmentTotal
Female15215449181355378
Male312246592348551119251851
08

Study locations

2 sites
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Zhengzhou, China
09

References and documents

Publications

  • Han J, Dai L, Zhong N, Young D. Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions. COPD. 2015 Apr;12(2):115-25. doi: 10.3109/15412555.2014.974741. Epub 2014 Dec 4. PubMed 25474373 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2013 to primary completion in May 2015, 27 months.

Results were first posted in Sep 2019, 4 years 4 months after primary completion.

Of 71 industry-sponsored phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 27 months is above that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2013
First posted
Feb 20, 2013
StartActual
Feb 5, 2013
Primary completionActual
May 25, 2015
CompletionActual
May 25, 2015
Results first posted
Sep 26, 2019
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01794780
Responsible party
Sponsor
First posted
Feb 20, 2013
Start date
Feb 5, 2013
Primary completion
May 25, 2015
Completion
May 25, 2015
Results posted
Sep 26, 2019
Last update
Sep 26, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Indacaterol · Tiotropium · Salmeterol Xinafoate · Fluticasone · Budesonide · Formoterol

Start the discussion